Latest News | Lupin Inks Pact to Acquire Two Inhalation Brands from Sunovion for USD 75 Mn

New Delhi, Oct 20 (PTI) Drug maker Lupin on Thursday said it will acquire two inhalation brands from Sunovion Pharmaceuticals Inc for USD 75 million (around Rs 622 crore).

The drug firm has inked a pact with US-based Sunovion to acquire Brovana (arformoterol tartrate) inhalation solution and Xopenex HFA (levalbuterol tartrate) inhalation aerosol.

Also Read | Samsung Galaxy A24 Specifications Leaked Online: Report.

The Mumbai-based firm expects the transaction to be accretive to earnings in the first year.

The acquisition of these two brands will expand the company's inhalation product portfolio in the US and strengthen its presence in the respiratory therapy area while continuing to provide patients access to these important medicines, Lupin said in a statement.

Also Read | 250 Million Monthly Active Devices Now Run Android Go, Says Google.

Brovana is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

Xopenex HFA is a short-acting beta2-adrenergic agonist (SABA), indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age or older with reversible obstructive airway disease.

"We remain focused on strengthening our respiratory franchise in the US. We have established a strong position in the respiratory segment with our Albuterol MDI and Brovana authorised generic launch," Lupin CEO Vinita Gupta stated.

The addition of these two brands enhances the company's position in the segment, she added.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)